• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用Toll样受体7激动剂(局部咪喹莫特)根除增殖性疣状白斑:一例报告

Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report.

作者信息

Townsend Melanie, Kejner Alexandra E, Nourollah-Zadeh Farzad, Rizzante Fabio A P, Woods Tina R, Rathore Sonali, Alterman Douglas, Teich Sorin, Albergotti William G, Newman Jason G, Yoon Angela J

机构信息

Department of Otolaryngology Head and Neck Surgery and Communicative Disorders, University of Louisville, Louisville, KY, United States.

Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, SC, United States.

出版信息

Front Oncol. 2024 Nov 15;14:1473889. doi: 10.3389/fonc.2024.1473889. eCollection 2024.

DOI:10.3389/fonc.2024.1473889
PMID:39619444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11604604/
Abstract

Proliferative verrucous leukoplakia (PVL) is an aggressive and distinct type of oral precancerous lesion characterized by warty surfaced white plaque diffusely involving oral mucosa. Surgical excision is the treatment of choice. However, PVL has persistent and recurrent growth patterns, requiring multiple surgical procedures. Surgical intervention is especially challenging if PVL extends between teeth limiting access. These interproximally located lesions have a high propensity to undergo malignant transformation. We report a case of a 53-year-old man with recurrent PVL diffusely covering the maxillary and mandibular gingiva. Despite complete surgical excisions, PVL recurred, and a focal area in the interproximal mandibular gingiva progressed to invasive squamous cell carcinoma requiring marginal resection. The remaining PVL areas were treated with topical imiquimod (toll-like receptor 7 agonist) for six months, resulting in complete clinical and histological resolution. Topical agents can cover a larger surface area and penetrate in between interproximal areas. Importantly, it allows for maximal local exposure with minimal systemic toxicity, essential for long-term treatment and prophylactic use of the agent to prevent relapse.

摘要

增殖性疣状白斑(PVL)是一种侵袭性且独特的口腔癌前病变,其特征为表面呈疣状的白色斑块,广泛累及口腔黏膜。手术切除是首选治疗方法。然而,PVL具有持续和复发的生长模式,需要多次手术。如果PVL在牙齿之间扩展,限制了手术入路,手术干预尤其具有挑战性。这些位于牙间隙的病变极易发生恶变。我们报告一例53岁男性,复发性PVL广泛覆盖上颌和下颌牙龈。尽管进行了完整的手术切除,PVL仍复发,下颌牙间隙牙龈的一个局灶性区域进展为浸润性鳞状细胞癌,需要进行边缘切除。其余PVL区域外用咪喹莫特(Toll样受体7激动剂)治疗6个月,临床和组织学均完全消退。外用药物可以覆盖更大的表面积,并渗透到牙间隙区域。重要的是,它能在全身毒性最小的情况下实现最大程度的局部暴露,这对于长期治疗以及预防性使用该药物以防止复发至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d59/11604604/29390413a5c2/fonc-14-1473889-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d59/11604604/c5aa6bd1d6f4/fonc-14-1473889-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d59/11604604/29390413a5c2/fonc-14-1473889-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d59/11604604/c5aa6bd1d6f4/fonc-14-1473889-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d59/11604604/29390413a5c2/fonc-14-1473889-g002.jpg

相似文献

1
Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report.使用Toll样受体7激动剂(局部咪喹莫特)根除增殖性疣状白斑:一例报告
Front Oncol. 2024 Nov 15;14:1473889. doi: 10.3389/fonc.2024.1473889. eCollection 2024.
2
Proliferative verrucous leukoplakia: Case study of 24 years and outcome of treatment with CO laser.增殖性疣状白斑:24年病例研究及CO激光治疗结果
Clin Adv Periodontics. 2024 Oct 24. doi: 10.1002/cap.10320.
3
Expanded Expression of Toll-Like Receptor 2 in Proliferative Verrucous Leukoplakia.Toll样受体2在增殖性疣状白斑中的表达增加
Head Neck Pathol. 2019 Dec;13(4):635-642. doi: 10.1007/s12105-019-01028-y. Epub 2019 Mar 19.
4
Proliferative verrucous leukoplakia: an aggressive form of oral leukoplakia.增殖性疣状白斑:一种侵袭性口腔白斑。
J Dent Hyg. 2004 Summer;78(3):7. Epub 2004 Jun 1.
5
Malignant transformation of proliferative Verrucous Leukoplakia-systematic review & meta-analysis.增殖性疣状白斑的恶性转化——系统评价与荟萃分析
BMC Oral Health. 2025 Feb 1;25(1):175. doi: 10.1186/s12903-025-05565-7.
6
Proliferative Verrucous Leukoplakia Presenting as a Ring Around the Collar and Cancer: A Case Report.表现为领口周围环状及癌变的增殖性疣状白斑:一例报告
Cureus. 2024 Mar 13;16(3):e56077. doi: 10.7759/cureus.56077. eCollection 2024 Mar.
7
Proliferative verrucous leukoplakia and its related lesions.增殖性疣状白斑及其相关病变。
Oral Oncol. 1999 Jul;35(4):354-9. doi: 10.1016/s1368-8375(99)00007-x.
8
Proliferative verrucous leukoplakia: a clinicopathological comparative study.增殖性疣状白斑:一项临床病理对比研究。
Int J Oral Maxillofac Surg. 2022 Aug;51(8):1027-1033. doi: 10.1016/j.ijom.2022.01.002. Epub 2022 Jan 19.
9
Diode laser surgery in the treatment of oral proliferative verrucous leukoplakia associated with HPV-16 infection.二极管激光手术治疗与HPV-16感染相关的口腔增殖性疣状白斑
Maxillofac Plast Reconstr Surg. 2018 Jul 30;40(1):16. doi: 10.1186/s40902-018-0156-2. eCollection 2018 Dec.
10
Proliferative verrucous leukoplakia: an elusive disorder.增殖性疣状白斑:一种难以捉摸的疾病。
J Evid Based Dent Pract. 2014 Jun;14 Suppl:147-53.e1. doi: 10.1016/j.jebdp.2014.04.005. Epub 2014 Apr 5.

本文引用的文献

1
How safe is off-label use of imiquimod in oral lesions?咪喹莫特在口腔病损中的超适应证用药安全性如何?
Evid Based Dent. 2024 Dec;25(4):176-177. doi: 10.1038/s41432-024-01026-2. Epub 2024 Jun 12.
2
Proliferative verrucous leukoplakia: a general dental practitioner-focused clinical review.增殖性疣状白斑:以普通牙科医生为重点的临床综述。
Br Dent J. 2024 Feb;236(4):297-301. doi: 10.1038/s41415-024-7066-8. Epub 2024 Feb 23.
3
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.节拍化疗与药物重新利用:肿瘤学中的范式转变。
Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15.
4
Is imiquimod a promising drug to treat oral mucosa diseases? A scoping review and new perspectives.咪喹莫特治疗口腔黏膜疾病是否有前景? 系统评价和新视角。
Br J Clin Pharmacol. 2024 Feb;90(2):427-439. doi: 10.1111/bcp.15923. Epub 2023 Oct 29.
5
Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management.咪喹莫特罕见的皮肤副作用:作用机制、诊断及处理综述
Dermatol Ther (Heidelb). 2023 Sep;13(9):1909-1934. doi: 10.1007/s13555-023-00978-0. Epub 2023 Aug 1.
6
An Alternative Device for the Topical Treatment of Oral Cancer: Development and Ex-Vivo Evaluation of Imiquimod-Loaded Polysaccharides Formulations.一种用于口腔癌局部治疗的替代装置:咪喹莫特负载多糖制剂的研发与离体评价
Pharmaceutics. 2022 Nov 23;14(12):2573. doi: 10.3390/pharmaceutics14122573.
7
Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase.口腔滤泡状乳头瘤病:奥罗昔单抗局部治疗。
Clin Exp Dent Res. 2022 Aug;8(4):858-862. doi: 10.1002/cre2.557. Epub 2022 Apr 13.
8
Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod.咪喹莫特引起的局部皮肤反应及流感样体征和症状的出现。
JAAD Int. 2022 Mar 30;7:113-118. doi: 10.1016/j.jdin.2022.01.010. eCollection 2022 Jun.
9
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.局部应用咪喹莫特和帕博利珠单抗治疗复发性口腔黏膜黑色素瘤可实现完全组织病理学缓解。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2020-001219.
10
Recurrences following treatment of proliferative verrucous leukoplakia: A systematic review and meta-analysis.治疗增殖性疣状白斑后的复发:系统评价和荟萃分析。
J Oral Pathol Med. 2021 Sep;50(8):820-828. doi: 10.1111/jop.13178. Epub 2021 Apr 13.